Trustmark National Bank Trust Department’s AstraZeneca AZN Stock Holding History

Trustmark National Bank Trust Department’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-205	Closed	-$17K	–	579
2019 Q1	$17K	Hold	205	–	–	﹤0.01%	427
2018 Q4	$16K	Hold	205	–	–	﹤0.01%	420
2018 Q3	$16K	Buy	+205	New	+$15.5K	﹤0.01%	448
2018 Q2	–	Sell	-5,253	Closed	-$367K	–	235
2018 Q1	$367K	Sell	5,253 -1,750	-25%	-$121K	0.04%	195
2017 Q4	$486K	Sell	7,003 -96	-1%	-$6.47K	0.05%	187
2017 Q3	$481K	Buy	7,099 +876	+14%	+$55.3K	0.06%	181
2017 Q2	$424K	Hold	6,223	–	–	0.05%	197
2017 Q1	$387K	Buy	6,223 +2,404	+63%	+$140K	0.05%	196
2016 Q4	$209K	Hold	3,819	–	–	0.03%	239
2016 Q3	$251K	Buy	+3,819	New	+$250K	0.03%	229

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Trustmark National Bank Trust Department's AZN Position: Q2 2019 in Review

Trustmark National Bank Trust Department sold out of AstraZeneca (AZN) in Q2 2019, closing a stake of 205 shares — an estimated $17K sold.

Trustmark National Bank Trust Department first reported a position in AZN in Q3 2016 and held it in 10 quarters. The position peaked at $486K in Q4 2017. 546 funds tracked by Wall St. Rank hold AZN as of Q2 2019.

Trustmark National Bank Trust Department reported no remaining AstraZeneca position as of Q2 2019 after selling out during the quarter.
Trustmark National Bank Trust Department sold 205 AstraZeneca shares in Q2 2019, an estimated $17K.
Trustmark National Bank Trust Department first reported a position in AstraZeneca in Q3 2016 and held it in 10 quarters.
Trustmark National Bank Trust Department's AstraZeneca position peaked at $486K in Q4 2017.
546 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2019.

Based on Trustmark National Bank Trust Department's 13F filing for Q2 2019, filed 13 Aug 2019.